Salivary metabolomic biomarkers for esophageal and gastric cancers by liquid chromatography–mass spectrometry

IF 4.5 2区 医学 Q1 ONCOLOGY Cancer Science Pub Date : 2024-07-14 DOI:10.1111/cas.16256
Kosuke Nakane, Koichi Yagi, Sho Yajima, Sachiyo Nomura, Masahiro Sugimoto, Yasuyuki Seto
{"title":"Salivary metabolomic biomarkers for esophageal and gastric cancers by liquid chromatography–mass spectrometry","authors":"Kosuke Nakane,&nbsp;Koichi Yagi,&nbsp;Sho Yajima,&nbsp;Sachiyo Nomura,&nbsp;Masahiro Sugimoto,&nbsp;Yasuyuki Seto","doi":"10.1111/cas.16256","DOIUrl":null,"url":null,"abstract":"<p>Early detection of esophageal and gastric cancers is essential for patients' prognosis; however, optimal noninvasive screening tests are currently not available. Saliva is a biofluid that is readily available, allowing for frequent screening tests. Thus, we explored salivary diagnostic biomarkers for esophageal and gastric cancers using metabolomic analyses. Saliva samples were collected from patients with esophageal (<i>n</i> = 50) and gastric cancer (<i>n</i> = 63), and patients without cancer as controls (<i>n</i> = 20). Salivary metabolites were analyzed by liquid chromatography–mass spectrometry to identify salivary biomarkers. We also examined the metabolic profiles of gastric cancer tissues and compared them with the salivary biomarkers. The sensitivity of the diagnostic models based on salivary biomarkers was assessed by comparing it with that of serum tumor markers. Additionally, using postoperative saliva samples collected from patients with gastric cancer, we analyzed the changes in the biomarkers' concentrations before and after surgery. Cytosine was detected as a salivary biomarker for gastric cancer, and cytosine, 2-oxoglutarate, and arginine were detected as salivary biomarkers for esophageal cancer. Cytidine, a cytosine nucleotide, showed decreased concentrations in gastric cancer tissues. The sensitivity of the diagnostic models for esophageal and gastric cancers was 66.0% and 47.6%, respectively, while that of serum tumor markers was 40%. Salivary cytosine concentration increased significantly postoperatively relative to the preoperative value. In summary, we identified salivary biomarkers for esophageal and gastric cancers, which showed diagnostic sensitivity at least comparable to that of serum tumor markers. Salivary metabolomic tests could be promising screening tests for these types of cancer.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"3089-3098"},"PeriodicalIF":4.5000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16256","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16256","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Early detection of esophageal and gastric cancers is essential for patients' prognosis; however, optimal noninvasive screening tests are currently not available. Saliva is a biofluid that is readily available, allowing for frequent screening tests. Thus, we explored salivary diagnostic biomarkers for esophageal and gastric cancers using metabolomic analyses. Saliva samples were collected from patients with esophageal (n = 50) and gastric cancer (n = 63), and patients without cancer as controls (n = 20). Salivary metabolites were analyzed by liquid chromatography–mass spectrometry to identify salivary biomarkers. We also examined the metabolic profiles of gastric cancer tissues and compared them with the salivary biomarkers. The sensitivity of the diagnostic models based on salivary biomarkers was assessed by comparing it with that of serum tumor markers. Additionally, using postoperative saliva samples collected from patients with gastric cancer, we analyzed the changes in the biomarkers' concentrations before and after surgery. Cytosine was detected as a salivary biomarker for gastric cancer, and cytosine, 2-oxoglutarate, and arginine were detected as salivary biomarkers for esophageal cancer. Cytidine, a cytosine nucleotide, showed decreased concentrations in gastric cancer tissues. The sensitivity of the diagnostic models for esophageal and gastric cancers was 66.0% and 47.6%, respectively, while that of serum tumor markers was 40%. Salivary cytosine concentration increased significantly postoperatively relative to the preoperative value. In summary, we identified salivary biomarkers for esophageal and gastric cancers, which showed diagnostic sensitivity at least comparable to that of serum tumor markers. Salivary metabolomic tests could be promising screening tests for these types of cancer.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用液相色谱-质谱法研究食管癌和胃癌的唾液代谢组生物标记物
早期发现食管癌和胃癌对患者的预后至关重要;然而,目前还没有最佳的无创筛查测试。唾液是一种很容易获得的生物流体,可以进行频繁的筛查测试。因此,我们利用代谢组学分析探索了食管癌和胃癌的唾液诊断生物标志物。我们收集了食管癌(50 人)和胃癌(63 人)患者的唾液样本,以及作为对照的非癌症患者(20 人)的唾液样本。通过液相色谱-质谱法分析唾液代谢物,以确定唾液生物标志物。我们还研究了胃癌组织的代谢谱,并将其与唾液生物标记物进行了比较。通过与血清肿瘤标记物进行比较,评估了基于唾液生物标记物的诊断模型的灵敏度。此外,我们还利用胃癌患者术后唾液样本,分析了手术前后生物标志物浓度的变化。结果发现,胞嘧啶是胃癌的唾液生物标志物,而胞嘧啶、2-氧代戊二酸和精氨酸则是食管癌的唾液生物标志物。胞嘧啶(一种胞嘧啶核苷酸)在胃癌组织中的浓度有所下降。诊断模型对食管癌和胃癌的灵敏度分别为 66.0% 和 47.6%,而血清肿瘤标志物的灵敏度为 40%。与术前相比,术后唾液胞嘧啶浓度明显升高。总之,我们发现了食管癌和胃癌的唾液生物标志物,其诊断灵敏度至少与血清肿瘤标志物相当。唾液代谢组学检测有望成为这些类型癌症的筛查检测方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
期刊最新文献
Issue Information In this issue Issue Information In this issue Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1